These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

72 related items for PubMed ID: 2436757

  • 1. Phase II trial of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in non-Hodgkin's lymphoma: prospective comparison of response with deoxycytidine kinase activity.
    Leiby JM, Snider KM, Kraut EH, Metz EN, Malspeis L, Grever MR.
    Cancer Res; 1987 May 15; 47(10):2719-22. PubMed ID: 2436757
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Metabolism and chemotherapeutic activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia L1210 and evidence for its phosphorylation by deoxycytidine kinase.
    Brockman RW, Cheng YC, Schabel FM, Montgomery JA.
    Cancer Res; 1980 Oct 15; 40(10):3610-5. PubMed ID: 6254636
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Fludarabine single-agent therapy for relapsed low-grade non-Hodgkin's lymphomas: a phase II study of the German Low-Grade Non-Hodgkin's Lymphoma Study Group.
    Hiddemann W, Unterhalt M, Pott C, Wörmann B, Sandford D, Freund M, Engert A, Gassmann W, Holtkamp W, Seufert J.
    Semin Oncol; 1993 Oct 15; 20(5 Suppl 7):28-31. PubMed ID: 8235693
    [Abstract] [Full Text] [Related]

  • 9. Phase II study of intravenous idarubicin in unfavorable non-Hodgkin's lymphoma.
    Case DC, Gerber MC, Gams RA, Crawford J, Votaw ML, Higano CS, Pruitt BT, Gould J.
    Cancer Res; 1992 Jul 15; 52(14):3871-4. PubMed ID: 1617662
    [Abstract] [Full Text] [Related]

  • 10. Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in patients with relapsed leukemia.
    Danhauser L, Plunkett W, Liliemark J, Gandhi V, Iacoboni S, Keating M.
    Leukemia; 1987 Sep 15; 1(9):638-43. PubMed ID: 3478543
    [Abstract] [Full Text] [Related]

  • 11. Disposition of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-phosphate in mice and dogs.
    Noker PE, Duncan GF, El Dareer SM, Hill DL.
    Cancer Treat Rep; 1983 May 15; 67(5):445-56. PubMed ID: 6189605
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effects on human peripheral lymphocytes of in vivo administration of 9-beta-D-arabinofuranosyl-2-fluoroadenine-5'-monophosphate (NSC 312887), a new purine antimetabolite.
    Boldt DH, Von Hoff DD, Kuhn JG, Hersh M.
    Cancer Res; 1984 Oct 15; 44(10):4661-6. PubMed ID: 6205751
    [Abstract] [Full Text] [Related]

  • 14. [A phase II study of mitoxantrone in refractory and relapsed malignant lymphomas. Cooperative Study Group of Mitoxantrone in Malignant Lymphomas].
    Kimura I, Ohnoshi T, Ogawa M, Sampi K, Masaoka T, Yamada K, Ohta K, Kitani T, Kawagoe H, Shirakawa S.
    Gan To Kagaku Ryoho; 1986 Sep 15; 13(9):2800-6. PubMed ID: 3753026
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Fludarabine phosphate therapy of non-Hodgkin's lymphoma.
    Hochster H, Cassileth P.
    Semin Oncol; 1990 Oct 15; 17(5 Suppl 8):63-5. PubMed ID: 1699284
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate.
    Malspeis L, Grever MR, Staubus AE, Young D.
    Semin Oncol; 1990 Oct 15; 17(5 Suppl 8):18-32. PubMed ID: 1699279
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non-Hodgkin lymphoma.
    Borghaei H, Millenson M, Schilder R, Alden M, Rogatko A, Wang H, Padavic-Shaller K, Smith MR.
    Cancer; 2004 Nov 01; 101(9):2034-41. PubMed ID: 15455357
    [Abstract] [Full Text] [Related]

  • 20. Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas.
    Borchmann P, Morschhauser F, Parry A, Schnell R, Harousseau JL, Gisselbrecht C, Rudolph C, Wilhelm M, Günther H, Pfreundschuh DM, Camboni G, Engert A.
    Haematologica; 2003 Aug 01; 88(8):888-94. PubMed ID: 12935976
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.